Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAKI-ACLF: Vitamin C in ACLF With Septic Shock and AKI
NCT07184866Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Apr 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial in acute-on-chronic liver failure (ACLF), septic shock and acute kidney injury (AKI) comparing Standard of Care (SOC) with Vitamin C + Standard of Care (2 arms). Primary endpoint: Resolution of septic shock at 96 hours. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ascorbic acid
03
Conditions
acute-on-chronic liver failure (ACLF)septic shockacute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07184866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184866.